In another study, Tølbøl et al. employed a diet-induced obesity (DIO) NASH mouse model as well as ob/ob mice, which were treated with liraglutide, obeticholic acid (a farnesoid-X-receptor [FXR]), or elafibranor (a dual proliferator-activated receptor-a/δ [PPAR-α/δ]) for 8 weeks [12]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.